Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PURE Bioscience's Total Assets for the quarter that ended in Apr. 2026 was $1.56 Mil.
During the past 12 months, PURE Bioscience's average Total Assets Growth Rate was 11.20% per year.
During the past 3 years, the average Total Assets Growth Rate was -12.80% per year.
During the past 5 years, the average Total Assets Growth Rate was -26.50% per year.
During the past 10 years, the average Total Assets Growth Rate was -13.10% per year.
During the past 13 years, PURE Bioscience's highest 3-Year average Total Assets Growth Rate was 71.00%. The lowest was -37.40%. And the median was 1.30%.
Note:
The Net Income data used here is four times the quarterly (Apr. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
PURE Bioscience's Asset Turnover for the quarter that ended in Apr. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
PURE Bioscience Total Assets Related Terms
PURE Bioscience Total Assets Historical Data
* Premium members only.
The historical data trend for PURE Bioscience's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
PURE Bioscience's Total Assets for the fiscal year that ended in Jul. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PURE Bioscience (PURE) has a Total Assets of $1.56 Mil as of Apr. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on PURE Bioscience and its competitors.
Is PURE Bioscience's Total Assets too high?
PURE Bioscience's current Total Assets is $1.56 Mil.
How does PURE Bioscience's Total Assets compare to DQWS and RAY?
PURE Bioscience's Total Assets of $1.56 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Consumer Packaged Goods company?
A good Total Assets depends on the Consumer Packaged Goods industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on PURE Bioscience and its competitors. PURE Bioscience's current Total Assets is $1.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PURE Bioscience stock overvalued right now?
Based on GuruFocus' analysis, PURE Bioscience (PURE) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.10, compared to a current price of $0.08 — trading 23.3% below its estimated fair value. The current Total Assets is $1.56 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For PURE Bioscience (PURE), the current Total Assets is $1.56 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, and products preserved with SDC and SDC as a raw material ingredient for manufacturing use. The company generates revenue from the sale of its antimicrobial products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PURE has been successfully added to your 
